WEIKANG BIO-TECHNOLOGY GROUP CO., INC.
company.status.inactiveCIK 1484042fmd_08GMTXSNPR5R152H3FATJASA52Manufacturing · Medicinal Chemicals & Botanical ProductsTemplate: Standard
Coverage: Jan 01, 2010 to Sep 30, 2012, 10 periods
Latest annual · FY2011
Millions- Total revenues
- 102
- Gross profit
- 60
- Operating income
- 42
- Net income
- 30
- Free cash flow
- 16
Latest quarter · Q3 FY2012
Millions- Total revenues
- 11
- Gross profit
- 6
- Operating income
- 5
- Net income
- 4
- Free cash flow
- 4
WEIKANG BIO-TECHNOLOGY GROUP CO., INC. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2011 | FY2010 | Change | Source |
|---|---|---|---|---|
| Revenue | $101.7 million | $74.6 million | +36.4% | 10-K 2012-03-30 · proof |
| Gross profit | $59.6 million | $45 million | +32.4% | 10-K 2012-03-30 · proof |
| Operating income | $42.3 million | $33.7 million | +25.6% | 10-K 2012-03-30 · proof |
| Net income | $29.6 million | $24.4 million | +21.3% | 10-K 2012-03-30 · proof |
| Cash from operating activities | $30.5 million | $34.2 million | -10.9% | 10-K 2012-03-30 · proof |
| Free cash flow | $15.6 million | $34.1 million | -54.4% | 10-K 2012-03-30 · proof |
| Total assets | $123.2 million | $78.6 million | +56.7% | 10-K 2012-03-30 · proof |
| Total liabilities | $11.1 million | $11.7 million | -5% | 10-K 2012-03-30 · proof |
| Cash and cash equivalents | $70.8 million | $50.4 million | +40.5% | 10-K 2012-03-30 · proof |
- What was WEIKANG BIO-TECHNOLOGY GROUP CO., INC.'s revenue in fiscal 2011?
- WEIKANG BIO-TECHNOLOGY GROUP CO., INC. reported revenue of $101.7 million for fiscal 2011 (the year ended Dec 31, 2011), against $74.6 million the year before (+36.4%). Source: the 10-K filed with the SEC on Mar 30, 2012. SEC
- What was WEIKANG BIO-TECHNOLOGY GROUP CO., INC.'s gross profit in fiscal 2011?
- WEIKANG BIO-TECHNOLOGY GROUP CO., INC. reported gross profit of $59.6 million for fiscal 2011 (the year ended Dec 31, 2011), against $45 million the year before (+32.4%). Source: the 10-K filed with the SEC on Mar 30, 2012. SEC
- What was WEIKANG BIO-TECHNOLOGY GROUP CO., INC.'s operating income in fiscal 2011?
- WEIKANG BIO-TECHNOLOGY GROUP CO., INC. reported operating income of $42.3 million for fiscal 2011 (the year ended Dec 31, 2011), against $33.7 million the year before (+25.6%). Source: the 10-K filed with the SEC on Mar 30, 2012. SEC
- What was WEIKANG BIO-TECHNOLOGY GROUP CO., INC.'s net income in fiscal 2011?
- WEIKANG BIO-TECHNOLOGY GROUP CO., INC. reported net income of $29.6 million for fiscal 2011 (the year ended Dec 31, 2011), against $24.4 million the year before (+21.3%). Source: the 10-K filed with the SEC on Mar 30, 2012. SEC
- What was WEIKANG BIO-TECHNOLOGY GROUP CO., INC.'s cash from operating activities in fiscal 2011?
- WEIKANG BIO-TECHNOLOGY GROUP CO., INC. reported cash from operating activities of $30.5 million for fiscal 2011 (the year ended Dec 31, 2011), against $34.2 million the year before (-10.9%). Source: the 10-K filed with the SEC on Mar 30, 2012. SEC
- What was WEIKANG BIO-TECHNOLOGY GROUP CO., INC.'s free cash flow in fiscal 2011?
- WEIKANG BIO-TECHNOLOGY GROUP CO., INC. reported free cash flow of $15.6 million for fiscal 2011 (the year ended Dec 31, 2011), against $34.1 million the year before (-54.4%). Source: the 10-K filed with the SEC on Mar 30, 2012. SEC
- What are WEIKANG BIO-TECHNOLOGY GROUP CO., INC.'s total assets?
- As of Dec 31, 2011, WEIKANG BIO-TECHNOLOGY GROUP CO., INC. reported total assets of $123.2 million, against $78.6 million a year earlier (+56.7%). Source: the 10-K filed with the SEC on Mar 30, 2012. SEC
- What are WEIKANG BIO-TECHNOLOGY GROUP CO., INC.'s total liabilities?
- As of Dec 31, 2011, WEIKANG BIO-TECHNOLOGY GROUP CO., INC. reported total liabilities of $11.1 million, against $11.7 million a year earlier (-5%). Source: the 10-K filed with the SEC on Mar 30, 2012. SEC
- What are WEIKANG BIO-TECHNOLOGY GROUP CO., INC.'s cash and cash equivalents?
- As of Dec 31, 2011, WEIKANG BIO-TECHNOLOGY GROUP CO., INC. reported cash and cash equivalents of $70.8 million, against $50.4 million a year earlier (+40.5%). Source: the 10-K filed with the SEC on Mar 30, 2012. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1484042&period_type=annual&limit=5"Information only, not investment advice.